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Introduction
In spite of significant progress in therapeutic methods,
the prognosis in non-small cell lung cancer (NSCLC) is
still unsatisfactory [1]. It is believed that a better under-
standing of lung cancer biology and in particular the
molecular nature of the tumor may result in more
efficient cancer management.
One of the most extensively studied genetic
alterations in NSCLC are P53 gene abnormalities. The
P53 gene, called the “guardian of the genome”, is located
in 17p13 and encodes for a 53-kDa nuclear phospho-
protein (393 amino acids). The P53 gene is involved in cell
cycle control, DNA repair, cellular differentiation,
senescence, angiogenesis and particularly in apoptosis.
The protein product of the P53 gene causes cell cycle
arrest in response to DNA damage by inducing GADD45,
p21WAF1, PCNA and mdm2 expression [2]. Apart from
mutation, the function of this gene may be inactivated in
human tumors by several other mechanisms, including
altered subcellular localization of p53, association of p53
protein with viral proteins or binding of p53 protein to
mdm2 cellular oncoprotein [2, 3].
MDM2/HDM2 (mouse/human double minute) gene is
an evolutionary conserved oncogene located in 12q13-
14. It was originally identified in a tumorigenic derivative
of the mouse Balb/c cell line called 3T3DM, in which
MDM2 was amplified and overexpressed [4]. MDM2 gene
tumorigenic activity results from mdm2 protein over-
expression, which is possible due to three mechanisms:
MDM2 gene amplification, MDM2mRNA increased
transcription or enhanced mdm2 protein translation.
Currently little is known about the role of MDM2 in
physiological conditions [5].
A protein product of MDM2 is a 90-kDa onco-
protein, physically associated with p53 and inhibiting wt-
p53 transactivation function. This protein has also
transforming activity when it is overexpressed in murine
fibroblasts [3]. Mdm2 and p53 proteins form an auto-
regulatory feedback-loop in which p53 positively regulates
mdm2 levels, whereas mdm2 inhibits p53 expression and
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activity [3, 6, 7]. Mdm2 plays important functions not
only in the nucleus (by forming a complex with wt- or
mt-p53) [3, 5], but also via transcellular effects [8].
The prognostic relevance of mdm2 protein
expression in surgically treated NSCLC patients remains
unclear, especially in relation to p53 protein expression.
Higashiyama et al. [9] suggested that overexpression of
mdm2 protein (in mdm2+/p53- phenotype) was para-
doxically associated with better prognosis. In other
studies, however, the presence of mdm2 protein was
positively correlated with lymph node involvement [10] or
had no impact on survival [11]. Since the prognostic value
of mdm2 proteins expression in NSCLC is still a matter of
controversy, we decided to assess this issue in
a consecutive series of surgically treated NSCLC patients.
Material and methods
The study group included 123 NSCLC patients who underwent
curative pulmonary resection at the Department of Thoracic
Surgery, Medical University of Gdaƒsk, Poland, between 1994
and 1998. Tumor samples were formalin-fixed and paraffin-
embedded. Three independent pathologists (A.K., K.H.W. and
C.B.) assessed tumor type and grade using haematoxylin-eosin
stained sections. Stage of disease (pTNM) was determined, after
pathological examination of primary tumor and regional lymph
nodes.
Mdm2 protein expression [12] and p53 protein [13]
expression was assessed with the use of immunohistochemistry,
as previously described. Monoclonal antibodies: IF2 clone –
against mdm2 and Pab 1801 – against p53 were purchased from
Oncogene Science. Two independent observers (K.H.W. and
C.B.) assessed the immunostaining. Any nuclear staining
for mdm2 was regarded positive (≥1%). Data base included
the following characteristics: age, sex, smoking habit, tumor
histology and degree of differentiation, stage of disease, pTNM
designations, date of surgery, adjuvant treatment, date and site
of recurrence, survival status including last follow-up or date of
death, as well as mdm2 and p53 expression.
S t a t i s t i c s
Chi2 and Fisher tests were used to assess the relation between
mdm2 and p53 expression, and clinical characteristics. Disease-
free survival (DFS) was calculated from the date of surgery to
the date of relapse or to the date of death, whichever occurred
first. Patient overall survival (OS) was calculated from the day of
surgery to the date of last follow-up or date of death. All
deceased patients were included in the survival analysis,
irrespective of cause of death. Survival curves were calculated
according to the Kaplan-Meier method and compared with the
use of the log-rank test. Multivariate analysis was based on the
Cox regression model with p values lower than 0.05 considered
as statistically significant.
Results
Nuclear expression of mdm2 protein was detected in 40
samples (33%). Co-expression of mdm2 and p53 was
found in 19 cases (15%). There was no correlation
between mdm2 and p53 protein expression even if various
cut-off values were taken.
In the chi2 analysis there was no correlation between
mdm2 expression (analyzed separately or jointly with
p53) and the clinical variables, including patient age and
sex, tumor type, grade and stage of disease (Table I).
Since only 6 patients (5%) in this series were never
smokers, the correlation between mdm2 protein
expression and smoking habit was not performed.
Table I. Correlation between mdm2 expression 
and clinicopathological variables
(Chi2 test)
Variable mdm2 (-) mdm2 (+) p
Age
>60 years 41 15 0.29
≤60 years 42 25
Sex
female 20 11 0.85
male 63 29
Stage
I 39 17 0.77
II 6 5
IIIA 35 16
IIIB + IV 3 2
Histology
squamous 41 23 0.48
adenous 24 3
large cell 10 2
adeno-squamous 8 2
Grade




negative 39 21 0.70
positive 44 19
At the time of this analysis (June 2005) 29 patients
(24%) remained free of disease. Median DFS for the
entire group was 28 months, and one- and five-year DFS
probability was 61% and 31%, respectively. Median DFS
for patients with and without mdm2 protein expression
was 12 and 31 months, respectively, and five-year DFS
probability was 25% and 35%, respectively (p=0.22).
There were no differences in DFS between four possible
mdm2/p53 phenotypes (mdm2-/p53-, mdm2-/p53+,
mdm2+/p53-, mdm2+/p53+) (Table II).
At the time of this analysis, with a median follow-up
of 71 months (range 52 to 113), 31 patients were alive
(25%). Median OS for the entire group was 34 months
and one- and five-year survival probability was 70% and
35%, respectively. Median survival for patients with and
without mdm2 expression was 16 months and 38 months,
respectively and 5-year survival probability was 24% and
40%, respectively (p=0.17).
There was no significant difference in overall survival
between particular groups of patients with four possible
mdm2/p53 phenotypes (Table II). There was a trend
though for increased overall and disease-free survival in
patients with mdm2-/p53+ phenotype (Figures 1A. and
1B.).
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In uni- and multivariate analysis stage of disease and
tumor grade were independent prognostic factors for
DFS and OS (Table III).
Discussion
In our study, mdm2 protein expression was found in 33%
of NSCLC cases. The frequency of mdm2 expression in
other lung cancer series ranged widely from 6 to 78% [9-
11, 14-16]. These large discrepancies may be due to
several factors. One of them seems to be the type of
primary antibody and detection system. We used the
APAAP (alkaline phosphatase anti-alkaline phosphatase)
technique, whereas other authors used the ABC complex
(avidin-biotin-peroxidase) [9, 14] or SAB (strepavidin-
biotin-peroxidase) system [11, 17]. Similarly to other
authors [9, 10, 14, 15, 17], in this study IF2 clone was
used to detect mdm2 protein. This antibody recognizes
–NH2 terminal region of mdm2. Other authors used 1B10
clone recognizing –COOH terminal region of mdm2
protein [10, 15], or SMP-14 clone recognizing mdm2
epitopes located between 154-167 amino acids of mdm2
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Table II. The impact of joint mdm2 and p53 expression on DFS and OS
Patient subgroup No. (%) Disease-free survival Overall survival
p Hazard ratio p Hazard ratio
(95% CI) (95% CI)
mdm2-/p53- 39 
vs. others (32%) 0.72 1.08 (0.64-1.52) 0.67 1.10 (0.66-1.54)
mdm2-/p53+ 44 
vs. others (36%) 0.14 0.72 (0.29-1.15) 0.09 0.69 (0.24-1.12)
mdm2+/p53- 21 
vs. others (17%) 0.37 1.27 (0.75-1.79) 0.28 1.34 (0.83-1.86)
mdm2+/p53+ 19 
vs. others (15%) 0.52 1.20 (0.66-1,76) 0.51 1.20 (0.65-1.76)
Figure 1A. Kaplan-Meyer survival curves for p53(+)/mdm2(-)
phenotype vs others - disease-free survival
Figure 1B. Kaplan-Meyer survival curves for p53(+)/mdm2(-)
phenotype vs others – overall survival
Table III. Multivariate Cox proportional hazard model of DFS and OS
Variable Disease-free survival Overall survival
p HR (95% CI) p HR (95% CI)
Sex 0.77 0.94 (0.53-1.35) 0.93 0.98 (0.57-1.39)
Age 0.07 1.40 (1.03-1.76) 0.06 1.50 (1.12-1.87)
Histology 0.42 1.06 (0.92-1.21) 0.50 1.05 (0.90-1.20)
Stage of disease <0.001 1.52 (1.36-1.69) <0.001 1.58 (1.40-1.74)
Grade 0.01 1.47 (1.17-1.77) 0.003 1.60 (1.30-1.92)
mdm2 status 0.56 0.84 (0.51-1.27) 0.75 0.94 (0.56-1.32)
p53 status 0.64 0.92 (0.58-1.27) 0.67 0.93 (0.58-1.28)
HR – hazard ratio, 95% CI – 95% confidence interval
[11]. There is no commercially available p53 antibody
able to distinguish the exact form of accumulated p53
protein (wild or mutated type). Therefore, studies
addressing p53 expression in NSCLC can not define the
mechanism of p53 accumulation. Similarly, the cause of
mdm2 overexpression is unknown, especially in the
mdm2-p53 auto-regulatory feedback-loop context.
In this study, we considered as positive samples
showing only nuclear expression of mdm2 protein. Some
authors included also cases with protein located outside
the nucleus e.g. in the cytoplasm [14]. There were also
differences in cut-off values. Some authors considered
as positive samples showing >0% [14], >5% [18] or
>10% of positive cells [9, 10, 15]. Marchetti et al. [14] did
not report the criterion of mdm2 positivity, whereas the
cut-off value of >50% for p53 protein was taken. All
these factors preclude meaningful joint analysis of the
results obtained in particular studies.
There have been only a few studies addressing co-
expression of mdm2 and p53. In five studies [9, 10, 15, 16,
19] there was no correlation between expression of both
proteins and in one the presence of mdm2 coincided with
the high expression of p53 [14]. In our series, the co-
expression of mdm2 and p53 protein was found in 15% of
cases. There was no correlation between the expressions
of both proteins, even if the highest expression of p53
was considered (>50%). Some authors suggested that
the function of mdm2 is not limited to p53 regulation
[10]. It is likely that mdm2 may act in carcinogenesis
independently of p53, and that overexpression of this
proto-oncogene could lead to neoplasmatic transfor-
mation, also in the absence of other genetic disorders
[8].
In this study, similarly to Ko et al. [11], no correlation
between expression of mdm2 and p53 and clinicopatho-
logical features was observed (for both proteins analyzed
jointly or separately). Some studies demonstrated
increased mdm2 expression in lung adenocarcinomas [9,
14], whereas others (including ours) failed to show this
relation [11, 16, 17]. Similarly to other authors [9, 19],
we did not find correlation between mdm2 and tumor
grade or stage of disease. However, Gorgoulis et al. [10]
reported increased involvement of lymph nodes in tumors
with both mdm2 overexpression (p<0.005) and
mdm2+/p53+ phenotype (p<0.001). Akiawa et al. [16]
demonstrated that the presence of mdm2 was correlated
with p21WAF1/CIP1 protein expression and stage of disease,
but not with p53.
In this series, we did not find any influence of mdm2
expression on DFS and OS. To our knowledge, there have
been only five published studies addressing mdm2 protein
expression in NSCLC, of which only three analyzed the
prognostic value of mdm2.
Joint analysis of mdm2 and p53 expression in this
series failed to identify any phenotype related to
prognosis. This finding should however be interpreted
cautiously due to relatively small patient samples in
particular subpopulations. Akiawa et al. [16] reported no
prognostic value of mdm2/p53 protein expression in 112
NSCLC patients, despite more frequent mdm2 over-
expression in advanced disease. Ko et al. [11] observed no
influence of mdm2, p53 protein expression and P53 gene
mutation on survival, but the presence of MDM2 mRNA
was correlated with better prognosis. Higashiyama et al.
[9] suggested that expression of mdm2 and p53 analyzed
separately had no impact on survival (p=0.62), however
the mdm2+/p53- phenotype was correlated with better
prognosis (p=0.039). Gorgoulis et al. [10] demonstrated
worse prognosis and more frequent lymph node
involvement related to mdm2+/p53+ phenotype, but that
study did not include survival analysis.
In summary, our study suggests that the clinical
relevance of mdm2 expression be it with or without
accompanying p53 expression, remains questionable.
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